Production of High-Potency Concentrates of Antihemophilic Globulin in a Closed-Bag System

Abstract

REPLACEMENT therapy of classic hemophilia in this country is still handicapped by the low potency and high price of therapeutic materials. In this disease severely affected patients have less than 1 per cent of the mean normal circulating level of antihemophilic globulin (AHG, factor VIII). To stop various types of hemorrhage, minimum levels of 10 to 35 per cent must be achieved and maintained for one to twelve days. When one considers that frozen plasma has on the average 65 per cent of the antihemophilic globulin in the mean fresh sample, and when one further realizes that the half-life of . . .